Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Commences European trials of the InSynch ICD 34 Joule implantable cardioverter defibrillator for heart failure patients at risk of sudden cardiac death. The device features GEM DR ICD technology, a PR Logic dual chamber detection algorithm and Patient Alert performance monitoring. Both the InSynch ICD and the InSynch system (which provides cardiac resynchronization and was launched abroad in August 1998), are used with Medtronic's Attain model 2187 and 2188 left ventricular leads, which have been released outside the U.S. Both the InSynch and the Attain 2187 and 2188 leads are currently in clinical trials in the U.S. Separately, Medtronic announces the first human implants in Germany of the AT500, a 20 g, 14 cc dual chamber, rate responsive stimulator for bradycardia patients with intermittent atrial tachyarrhythmias and atrial fibrillations
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.